1-3 of 3
Eiko Yasui
Close
Sort by
Journal Articles

Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Eishi Ashihara, MD, PhD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Rina Nagao, Tatsutoshi Nakahata, M.D., Ph.D., Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2166.
https://doi.org/10.1182/blood.V114.22.2166.2166
Published: 2009
Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3185.
https://doi.org/10.1182/blood.V112.11.3185.3185
Published: 2008
Journal Articles

Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia.

Miki Takeuchi, Junya Kuroda, Shinya Kimura, Eishi Ashihara, Kazuo Umezawa, Eiko Yasui, Makoto Kawatani, Hiroyuki Osada, Keiko Hodohara, Yoshihide Fujiyama, Taira Maekawa
Journal: Blood
Blood (2007) 110 (11): 2931.
https://doi.org/10.1182/blood.V110.11.2931.2931
Published: 2007